Compare Meta Platforms Inc (META) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs TransMedics Group Inc — how do they compare? Meta Platforms Inc trades at $647.21 (market cap $1.64T), while TransMedics Group Inc trades at $74.81 (market cap $2.54B). The key difference: Meta Platforms Inc is far larger — about 645.7× TransMedics Group Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| META | TMDX | |
|---|---|---|
Market Cap | $1.64T | $2.54B |
Volume | 24,093,972 | — |
Sector | Media | Technology |
52-Week High | $790.00 | $150.42 |
52-Week Low | $525.72 | $61.99 |
Enterprise Value | $1.65T | $2.94B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $646.27, up 0.04% with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70. Revenue growth remains strong at $201B for 2025, while maintaining impressive profitability with 32.84% net income margin. Recent AI developments including Muse Spark launch and a $21B partnership with CoreWeave highlight continued innovation momentum.
The outlook remains positive with analyst consensus price target of $817.32 representing 26% upside potential. Key opportunities include AI monetization and infrastructure leadership, while risks involve regulatory lawsuits and high capital expenditures. Wall Street sentiment is strongly bullish with 79% buy ratings, though investors should monitor legal challenges and competitive pressures in the evolving AI landscape.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
